EB 02Alternative Names: EB-02
Latest Information Update: 02 Sep 2016
At a glance
- Originator Edesa Biotech
- Class Antihaemorrhagics
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Haemorrhoids
Most Recent Events
- 02 Sep 2016 Phase-I clinical trials in Haemorrhoids in Canada (Topical) before September 2016